See Melanotan II reconstitution trends, dosage distribution, and BAC water volumes from anonymized WPA peptide calculator sessions.
Melanotan II (MT-2) is a potent alpha-MSH analog typically dosed in the low-mcg range and reconstituted in small vial formats. This data reveals the dose amounts, vial sizes, and BAC water volumes researchers most commonly choose when mixing this melanocortin receptor agonist.
Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that originated from the alpha-MSH structure-activity work of Mac Hadley and Victor Hruby at the University of Arizona through the 1980s. The Hadley/Hruby program substituted D-amino acids and added a cyclic backbone to produce a molecule with substantially longer half-life and higher receptor affinity than native alpha-MSH, and the resulting non-selective agonism at the MC1, MC3, MC4, and MC5 melanocortin receptors drives the two effects MT-2 became known for: MC1-mediated melanin synthesis in skin melanocytes (the "tanning" effect), and MC3/MC4-mediated central nervous system effects on appetite and sexual arousal.
Melanotan II is a melanocortin research peptide most often sourced for tanning and appetite/libido research. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use — and several regulators have warned against use of unregulated supply.
Melanotan II is a non-selective agonist at the MC1R, MC3R, MC4R, and MC5R melanocortin receptors. MC1R activation in skin melanocytes drives eumelanin synthesis (the tanning effect); MC4R activation in the hypothalamus drives the appetite suppression and pro-erectile effects observed in human studies; MC3R/MC5R contribute to off-target sebaceous and immune effects.
Phase 1/2 trials in the 1990s in healthy volunteers and in patients with erectile dysfunction documented dose-dependent tanning, decreased appetite, spontaneous erections, and nausea. Development as a tanning drug was abandoned in favour of the MC4R-selective successor bremelanotide; melanotan II is no longer in any sponsor pipeline and is associated in post-market case reports with rhabdomyolysis, melanocytic-nevus darkening, and one published case of fatal kidney injury linked to unregulated supply.
Melanotan II has a reported half-life of ~33 hours, and the dose intervals researchers model most often fall around daily during titration. Long enough half-life that daily dosing produces meaningful buildup over the first week. This is part of why side effects (nausea, flushing) are typically worst during the loading phase, then settle. It is catalogued under Skin Peptides on WPA.
1,438 Melanotan II reconstitution calculations have been logged by the WPA community. The most common dose entered is 250mcg (481 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (1,318 sessions). The most common dosing frequency is daily (7x/week) (154 logged protocols), followed by once weekly (56).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.